Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Rhythm Biosciences Ltd. ( (AU:RHY) ) just unveiled an announcement.
Rhythm Biosciences Limited has released its financial report for the year ending June 30, 2025, highlighting its progress towards commercializing its ColoSTAT® product. This development positions the company to potentially impact the cancer diagnostics market by offering a reliable and cost-effective solution for early cancer detection, which could have significant implications for stakeholders and the industry.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Limited is an Australian publicly listed company in the medical diagnostics industry, focusing on developing simple and affordable blood tests for cancer detection. Its primary product, ColoSTAT®, is designed for the early and accurate detection of colorectal cancer and is nearing commercialization.
Average Trading Volume: 758,844
Technical Sentiment Signal: Buy
Current Market Cap: A$32.92M
For an in-depth examination of RHY stock, go to TipRanks’ Overview page.